Age (yr) |
61,7 ± 4,0 |
59,4 ± 3,9 |
0.407a
|
Body mass index (kg/m2) |
28,3 ± 1,7 |
27,2 ± 1,4 |
0.323 a
|
Number of men (n) |
25 (56.8%) |
30 (66.7%) |
0.339
b
|
Social level (n) |
|
|
|
1 |
19 (43.2%) |
14 (31.1%) |
0.419 b
|
2 |
7 (15.9%) |
11 (24.4%) |
|
3 |
18 (40.9%) |
20 (44.4%) |
|
Kidney failure (n) |
8 (18.2%) |
6 (13.3%) |
0.530
b
|
Liver failure (n) |
1 (2.3%) |
0 (0%) |
NA |
Number of total chronic disease (n) |
|
|
|
1 |
8 (18.2%) |
11 (24.4%) |
0.613 b
|
2 |
12 (27.3%) |
14 (31.1%) |
|
>2 |
24 (54.5%) |
20 (44.4%) |
|
Number of diseases involved in the study (n) |
|
|
|
1 |
36 (81.8%) |
37 (82.2%) |
0.960 b
|
Hypertension |
22 (50.0%) |
24 (53.3%) |
0.613
b
|
Type 2 diabetes |
7 (15.9%) |
5 (11.1%) |
|
Hypercholesterolemia |
7 (15.9%) |
8 (17.8%) |
|
2 |
8 (18.2%) |
7 (15.6%) |
0.777 b
|
Hypertension + Type 2 diabetes |
6 (13.6%) |
6 (13.3%) |
1
b
|
Hypertension + Hypercholesterolemia |
0 (0.0%) |
1 (2.2%) |
NA |
Type 2 diabetes + Hypercholesterolemia |
2 (4.5%) |
0 (0.0%) |
NA |
3 |
0 (0.0%) |
1 (2.2%) |
NA |
Number of different drugs prescribed |
6,2 ± 1,2 |
5,0 ± 0,8 |
0.118
a
|
Adjusted number of different drugs prescribed (n) |
|
|
|
<5 |
18 (40.9%) |
18 (40.0%) |
0.930
b
|
≥5 |
26 (59.1%) |
27 (60.0%) |
|
Side effects at the inclusion (n) |
11 (25.0%) |
9 (20%) |
0.572
b
|
Adherence score at the inclusion |
2,2 ± 0,4 |
2,0 ± 0,4 |
0.501
a
|
Patient with hypertension (n) |
28 (63.6%) |
32 (71.1%) |
0.452
b
|
used as primary outcome (n) |
28 (63.6%) |
27 (60.0%) |
0.724
b
|
Patient with type II diabetes (n) |
15 (34.1%) |
12 (26.7%) |
0.446
b
|
used as primary outcome (n) |
7 (15.9%) |
9 (20.0%) |
0.615
b
|
Patient with hypercholesterolemia (n) |
9 (20.5%) |
10 (22.2%) |
0.839
b
|
used as primary outcome (n) |
9 (20.5%) |
9 (20%) |
0.957
b
|
Lost of follow-up (n) |
5 (11.4%) |
11 (24.4%) |
0.108
b
|